Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

InSite Vision: DOUBle Trial Results are Disappointing-What Comes Next? (INSV.OB, $0.33)

Summary and Investment Thesis
InSite Vision (INSV.OB) just reported that topline results for AzaSite Plus and DexaSite in the DOUBle trial…
Read more…

InSite Vision: An Over-looked Company with Two Interesting Drug Candidates and a Big Upcoming Catalyst (INSV.OB, $0.31)

Results of the Important DOUBle Trial Are Imminent
During the May 8th quarterly conference call, management said that enrollment in the…
Read more…

Besivance Royalty Deal Extends InSiteís Cash Runway (INSV.OB, $0.31)

InSite Vision(INSV.OB) announced that it agreed to sell its royalty stream on future sales of Besivance, a product that is…
Read more…

InSite Vision: Positive Phase III Trial Results for BromSite Reduces Much of Downside Risk in the Stock (INSV.OB, $0.30)

BromSite Results are Strikingly Positive in First Phase III Trial
InSite Vision (INSV.OB) just announced top-line results from its first phase…
Read more…

InSite Vision: Upcoming Results on the DOUBle Trial May Not Be as Binary as I Have Been Thinking

I met with the CEO, Tim Ruane, and CFO, Lou Drapeau, of InSite Vision (INSV.OB) in early January during my…
Read more…

InSite Vision: Upcoming Topline Results from Clinical Trials Presents a Buying Opportunity (INSV.OB, $0.34)

Investment Overview and Opinion
In the first half of 2013, InSite Vision (INSV.OB) will release significant topline data from two phase…
Read more…

Hitting Major Milestones is Driving InSite's Price (INSV.OB, $0.40)

Investment Summary
InSite Vision (INSV.OB) has an aggressive and capable management team that continues to impressively execute on its game plan,…
Read more…

InSite Vision: Initiation of Coverage on Promising Late Stage Ophthalmology Company (INSV, $0.30)

Report Overview
The core technology of InSite Vision is its DuraSite delivery system that delivers drugs more effectively to the eye.…
Read more…

InSite Vision: Initiating Coverage on a Promising Company with a Robust Late Stage Product Portfolio

I have just published a new report and initiated coverage of InSite Vision (INSV, $0.30) with a Buy. The core…
Read more…